Lysophosphatidic acid activates telomerase in ovarian cancer cells through hypoxia-inducible factor-1α and the PI3K pathway

Journal of Cellular Biochemistry

Volumn 105, Issue 5, 2008, Pages 1194-1201

  Yang, Kun ^a   Zheng, Danhua ^a   Deng, Xiaoli ^a   Bai, Lin ^a   Xu, Yan ^b   Cong, Yu Sheng ^a  

^a BEIJING NORMAL UNIVERSITY   (China)

^b INDIANA UNIVERSITY   (United States)

Author keywords

HIF 1 ; hTERT; LPA; PI3K Akt; Telomerase

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; LYSOPHOSPHATIDIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL ACTIVATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME REACTIVATION; ENZYME REGULATION; HUMAN; HUMAN CELL; OVARY ADENOCARCINOMA; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL LINE, TUMOR; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYSOPHOSPHOLIPIDS; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; TELOMERASE;

EID: 57149113153     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21919     Document Type: Article

References (45)

1. Bárdos JI, Ashcroft M. 2005. Negative and positive regulation of HIF-1: A complex network. Biochim Biophys Acta 1755:107-120.
2. Baudhuin LM, Cristina KL, Lu J, Xu Y. 2002. Akt activation induced by lysophosphatidic acid and sphingosine-1-phosphate requires both mitogen-activated protein kinase kinase and p38 mitogen-activated protein kinase and is cell-line specific. Mol Pharmacol 62:660-671.
3. Bermudez Y, Yang H, Saunders BO, Cheng JQ, Nicosia SV, Kruk PA. 2007. VEGF- and LPA-induced telomerase in human ovarian cancer cells is Sp1-dependent. Gynecol Oncol 106:526-537.
4. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE. 1998. Extension of life-span by introduction of telomerase into normal human cells. Science 279:349-352.
5. Chou CH, Wei LH, Kuo ML, Huang YJ, Lai KP, Chen CA, Hsieh CY. 2005. Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-kappaB pathway by lysophosphatidic acid, an ovarian cancer-activating factor. Carcinogenesis 26:45-52.
6. Collins K. 2006. The biogenesis and regulation of telomerase holoenzymes. Nat Rev Mol Cell Biol 7:484-494.
7. Cong YS, Wright WE, Shay JW. 2002. Human telomerase and its regulation. Microbiol Mol Biol Rev 66:407-425.
8. Dong CK, Masutomi K, Hahn WC. 2005. Telomerase: Regulation, function and transformation. Crit Rev Oncol Hematol 54:85-93.
9. Drayton S, Rowe J, Jones R, Vatcheva R, Cuthbert-Heavens D, Marshall J, Fried M, Peters G. 2003. Tumor suppressor p16INK4a determines sensitivity of human cells to transformation by cooperating cellular oncogenes. Cancer Cell 4:301-310.
10. Dwyer J, Li H, Xu D, Liu JP. 2007. Transcriptional regulation of telomerase activity: Roles of the Ets transcription factor family. Ann NY Acad Sci 1114:36-47.
11. Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R, Hasegawa Y, Tanyi JL, LaPushin R, Eder A, Jaffe R, Erickson J, Mills GB. 2002. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta 1582:257-264.
12. Feeley KM, Wells M. 2001. Precursor lesions of ovarian epithelial malignancy. Histopathology 38:87-95.
13. Fishman DA, Liu Y, Ellerbroek SM, Stack MS. 2001. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res 61:3194-3199.
14. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A, Beijersbergen RL, Knoll JH, Meyerson M, Weinberg RA. 1999a. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 5:1164-1170.
15. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. 1999b. Creation of human tumour cells with defined genetic elements. Nature 400:464-468.
16. Harley CB. 2002. Telomerase is not an oncogene. Oncogene 21:494-502.
17. Herbert B, Pitts AE, Baker SI, Hamilton SE, Wright WE, Shay JW, Corey DR. 1999. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci USA 96:14276-14281.
18. Hu YL, Albanese C, Pestell RG, Jaffe RB. 2003. Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells. J Natl Cancer Inst 95:733-740.
19. Ke Q, Costa M. 2006. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 70:1469-1480.
20. Kim K, Sengupta S, Berk M, Kwak YG, Escobar PF, Belinson J, Mok SC, Xu Y. 2006. Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Res 66:7983-7990.
21. Lee J, Park SY, Lee EK, Park CG, Chung HC, Rha SY, Kim YK, Bae GU, Kim BK, Han JW, Lee HY. 2006. Activation of hypoxia-inducible factor-1alpha is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression. Clin Cancer Res 12:6351-6358.
22. Mills GB, Moolenaar WH. 2003. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3:582-591.
23. Mizumoto Y, Kyo S, Ohno S, Hashimoto M, Nakamura M, Maida Y, Sakaguchi J, Takakura M, Inoue M, Kiyono T. 2006. Creation of tumorigenic human endometrial epithelial cells with intact chromosomes by introducing defined genetic elements. Oncogene 25:5673-5682.
24. Moolenaar WH, van Meeteren LA, Giepmans BN. 2004. The ins and outs of lysophosphatidic acid signaling. Bioessays 26:870-881.
25. Nishi H, Nakada T, Kyo S, Inoue M, Shay JW, Isaka K. 2004. Hypoxia-inducible factor 1 mediates upregulation of telomerase (hTERT). Mol Cell Biol 24:6076-6083.
26. Park SY, Jeong KJ, Lee J, Yoon DS, Choi WS, Kim YK, Han JW, Kim YM, Kim BK, Lee HY. 2007. Hypoxia enhances LPA-induced HIF-1alpha and VEGF expression: Their inhibition by resveratrol. Cancer Lett 258:63-69.
27. Pectasides D, Pectasides E, Psyrri A, Economopoulos T. 2006. Treatment issues in clear cell carcinoma of the ovary: A different entity? Oncologist 11:1089-1094.
28. Pore N, Jiang Z, Shu HK, Bernhard E, Kao GD, Maity A. 2006. Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. Mol Cancer Res 4:471-479.
29. Pustilnik TB, Estrella V, Wiener JR, Mao M, Eder A, Watt MA, Bast RC, Jr., Mills GB. 1999. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res 5:3704-3710.
30. Ren J, Xiao YJ, Singh LS, Zhao X, Zhao Z, Feng L, Rose TM, Prestwich GD, Xu Y. 2006. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res 66:3006-3014.
31. Sako A, Kitayama J, Shida D, Suzuki R, Sakai T, Ohta H, Nagawa H. 2006. Lysophosphatidic acid (LPA)-induced vascular endothelial growth factor (VEGF) by mesothelial cells and quantification of host-derived VEGF in malignant ascites. J Surg Res 130:94-101.
32. Schwartz BM, Hong G, Morrison BH, Wu W, Baudhuin LM, Xiao YJ, Mok SC, Xu Y. 2001. Lysophospholipids increase interleukin-8 expression in ovarian cancer cells. Gynecol Oncol 81:291-300.
33. Semenza GL. 2003. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 10:721-732.
34. Sengupta S, Kim KS, Berk MP, Oates R, Escobar P, Belinson J, Li W, Lindner DJ, Williams B, Xu Y. 2007. Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion. Oncogene 26:2894-2901.
35. Shay JW, Bacchetti S. 1997. A survey of telomerase activity in human cancer. Eur J Cancer 33:787-791.
36. Shay JW, Wright WE. 2005. Senescence and immortalization: Role of telomeres and telomerase. Carcinogenesis 26:867-874.
37. Sivashanmugam P, Tang L, Daaka Y. 2004. Interleukin 6 mediates the lysophosphatidic acid-regulated cross-talk between stromal and epithelial prostate cancer cells. J Biol Chem 279:21154-21159.
38. Soslow RA. 2008. Histologic subtypes of ovarian carcinoma: An overview. Int J Gynecol Pathol 2:161-174.
39. Stewart SA, Weinberg RA. 2006. Telomeres: Cancer to human aging. Annu Rev Cell Dev Biol 22:531-557.
40. Xu Y, Fang XJ, Casey G, Mills GB. 1995. Lysophospholipids activate ovarian and breast cancer cells. Biochem J 309:933-940.
41. Xu Y, Shen Z, Wiper DW, Wu M, Morton E, Elson P, Kennedy AW, Belinson J, Markman M, Casey G. 1998. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 280:719-723.
42. Xu Y, Xiao YJ, Zhu K, Baudhuin LM, Lu J, Hong G, Kim KS, Cristina KL, Song L, S Williams F, Elson P, Markman M, Belinson J. 2003. Unfolding the pathophysiological role of bioactive lysophospholipids. Curr Drug Targets Immune Endocr Metabol Disord 3:23-32.
43. Zhang X, Mar V, Zhou W, Harrington L, Robinson MO. 1999. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev 13:2388-2399.
44. Zhou J, Schmid T, Frank R, Brune B. 2004. PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-independent degradation. J Biol Chem 279:13506-13513.
45. Zongaro S, de Stanchina E, Colombo T, D'Incalci M, Giulotto E, Mondello C. 2005. Stepwise neoplastic transformation of a telomerase immortalized fibroblast cell line. Cancer Res 65:11411-11418.